2-2.5x from an investment holding liquidation

(Full access for Lifetime Members only)

2-2.5x from an investment holding liquidation

12 November 2024

For many companies listed on AIM, there is now serious pressure to find a way to deal with their undervaluation.

In the case of this particular small-cap, it's clear that an outright liquidation will happen before too long. Hidden in the depths of legal documents, this company disclosed that management will receive 5% of all capital returned to shareholders.

The CEO could receive 20x his annual salary as a bonus. All he needs to do is liquidate the portfolio and return all proceeds to shareholders.

Underresearched by investors, this is an opportunity that shouldn't even exist – but it does, because hardly anyone is even following AIM stocks anymore.

The AIM market's suffering is your opportunity, if you know where to look.

This stock has limited liquidity, and piecing together this puzzle is valuable proprietary knowledge.

This opportunity is therefore exclusively available to Undervalued-Shares.com Lifetime Members.

Not a Lifetime Member yet? Sign up for a Membership - just USD 999/one-off.
Already a Lifetime Member? Log into your account to download the report.

Most recent

Latest reports (for Members only)

2-2.5x from an investment holding liquidation

2-2.5x from an investment holding liquidation

This AIM-listed small-cap will likely return all its capital to shareholders. Underresearched by investors, it's an opportunity that shouldn't even exist – but it does.

Ukraine reconstruction: one stock to benefit

Ukraine reconstruction: one stock to benefit

If or when the war in Ukraine ends, this stock will likely become the focus of investor money pushing into the country.

Actinium-225, aka "the world's rarest drug"

Actinium-225, aka "the world's rarest drug"

This little-known Western European company could become the global market leader for supplying the uber-rare "Ac-225", a potent weapon to treat cancer.